Kazuteru Ohashi

Hisashi Sakamaki7
Kazuhiko Kakihana6
7Hisashi Sakamaki
6Kazuhiko Kakihana
Learn More
In this paper, we present a novel global reordering model that can be incorporated into standard phrase-based statistical machine translation. Unlike previous local reordering models that emphasize the reordering of adjacent phrase pairs (Till-mann and Zhang, 2005), our model explicitly models the reordering of long distances by directly estimating the(More)
Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Because diagnosis of aGVHD is exclusively based on clinical symptoms and pathological findings, reliable and noninvasive laboratory tests for accurate diagnosis are required. An activating immunoreceptor, DNAM-1 (CD226), is(More)
  • Kaito Harada, Shuhei Kurosawa, Yutaro Hino, Keita Yamamoto, Masahiro Sakaguchi, Shuntaro Ikegawa +12 others
  • 2016
A high-flow nasal cannula (HFNC) is a newly developed device that enables high-flow oxygen therapy for patients with serious cardiopulmonary problems, but there are few data regarding its use in patients with hematological disease. The efficacy and tolerability of HFNCs for patients who developed ARF during the treatment of various hematological diseases(More)
To clarify the clinical impact of prior use of azacitidine (AZA) on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS), we retrospectively reviewed the clinical outcomes of 15 MDS patients who were treated with AZA before allo-HSCT (AZA group). We compared the outcomes of these 15 patients with 52(More)
INTRODUCTION Hepatitis B virus (HBV) flare is a serious problem following hematopoietic stem cell transplantation (HSCT), and the mortality rate is high if severe hepatitis occurs. CASE DESCRIPTION Although Entecavir (ETV) is a standard antiviral drug for HBV infection, the efficacy and safety of ETV therapy in HSCT are still unclear. DISCUSSION AND(More)
We retrospectively reviewed the medical records of 45 patients with relapsed acute leukemia after initial allogeneic hematopoietic stem ell transplantation (allo-HSCT). Among 45 patients, a total of 11 patients eventually underwent second allo-HSCT (HSCT-2). Median survival after relapse was 294 days (range, 135–942 days) for HSCT-2. Multivariate analysis(More)
We retrospectively analyzed the clinical outcomes of patients with pulmonary impairment before undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for the first time. Among 297 evaluable patients who underwent their first HSCT, 23 had restrictive, obstructive or mixed ventilatory impairment (n = 9, 13 and 1, respectively). Males(More)
  • 1